Berend Olivier

Utrecht University

Berend Olivier studied biology and got his PhD degree in Neurobiology at Groningen University. He worked for 22 years at Solvay Pharmaceuticals leading active research and development of psychoactive drugs, including antidepressants, antipsychotics and anxiolytics and a new group of drugs, serenics, aiming for reduction of pathological aggression. He was involved in research and development around fluvoxamine, a marketed SSRI antidepressant, anxiolytic and anti-OCD medicine. In 1999, he worked for 2 years in New York to set up a biotech start-up, PsychoGenics Inc., developing animal psychiatric and neurological (genetic) models in order to screen and find new psychoactive molecules. From 1992–2014, he was a professor of CNS Pharmacology at Utrecht University, performing research on animal models, brain mechanisms and pharmacology of psychiatric disorders.

2books edited

4chapters authored

Latest work with IntechOpen by Berend Olivier

Major depression is a severe and prevalent brain disorder with a high disability burden, hence the push for effective treatments. Antidepressants have been around since the 1950s, and although current medications are much more effective than early ones, there is still much room for improvement. "Real" antidepressants, defined as those that "repair" or "improve" the depression-causing mechanism in the brains of depressed patients, have yet to be identified. This book presents current research on depression and antidepressants, including use of antidepressants in alcohol use disorders and pregnancy, treatment-resistant depression, and development of potential new medications.

Go to the book